沙利度胺治疗小肠血管发育不良所致复发性出血
该多中心、双盲、随机、安慰剂对照试验纳入既往一年内至少4次出血、由小肠血管发育不良(SIA)所致复发性出血的患者150例,随机接受沙利度胺100 mg/d、50 mg/d或安慰剂口服4个月,治疗后随访至少1年。主要终点为有效应答,即治疗结束后一年内出血次数较治疗前一年减少至少50%。100 mg组、50 mg组和安慰剂组有效应答率分别为68.6%、51.0%和16.0%(三组同时比较P<0.001),次要终点分析支持主要终点结果。沙利度胺组不良事件总体上比安慰剂组更常见,具体包括便秘、嗜睡、肢体麻木、外周水肿、头晕和肝酶升高。
要点
- 纳入标准:既往一年内至少4次出血、由小肠血管发育不良所致的复发性出血患者。
- 沙利度胺100 mg/d口服4个月组有效应答率为68.6%,50 mg/d组为51.0%,安慰剂组为16.0%(三组同时比较P<0.001)。
- 有效应答定义为治疗结束后一年内出血次数较治疗前一年减少至少50%。
- 次要终点(出血停止且无再出血、输血、因出血住院、出血持续时间、血红蛋白水平)分析支持主要终点结果。
- 沙利度胺组不良事件总体上比安慰剂组更常见,包括便秘、嗜睡、肢体麻木、外周水肿、头晕和肝酶升高。
适用人群与场景
- 既往一年内至少4次出血、由小肠血管发育不良(SIA)所致复发性出血的患者。
诊断标准与关键阈值
- 有效应答定义:治疗结束后一年内出血次数较治疗前一年减少至少50%。
处置流程与药物剂量
- 沙利度胺100 mg或50 mg口服,每日一次,疗程4个月;治疗结束后随访至少1年。
研究设计与关键结果
- 多中心、双盲、随机、安慰剂对照试验,150例患者随机分组:沙利度胺100 mg组51例、50 mg组49例、安慰剂组50例。
- 有效应答率:100 mg组68.6%、50 mg组51.0%、安慰剂组16.0%(三组同时比较P<0.001)。
- 次要终点(出血停止且无再出血、输血、因出血住院、出血持续时间、血红蛋白水平)分析结果支持主要终点结果。
- 沙利度胺组不良事件总体上比安慰剂组更常见;具体不良事件包括便秘、嗜睡、肢体麻木、外周水肿、头晕和肝酶升高。
证据类型、等级与局限
- 证据类型:多中心、双盲、随机、安慰剂对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于既往一年内至少4次出血、由小肠血管发育不良所致复发性出血的患者,沙利度胺100 mg/d或50 mg/d口服4个月可减少出血,100 mg组有效应答率68.6%、50 mg组51.0%,均高于安慰剂组16.0%(三组同时比较P<0.001)。
- 使用沙利度胺时需注意不良事件总体上比安慰剂组更常见,包括便秘、嗜睡、肢体麻木、外周水肿、头晕和肝酶升高。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Recurrent bleeding from the small intestine accounts for 5 to 10% of cases of gastrointestinal bleeding and remains a therapeutic challenge. Thalidomide has been evaluated for the treatment of recurrent bleeding due to small-intestinal angiodysplasia (SIA), but confirmatory trials are lacking.
METHODS: We conducted a multicenter, double-blind, randomized, placebo-controlled trial to investigate the efficacy and safety of thalidomide for the treatment of recurrent bleeding due to SIA. Eligible patients with recurrent bleeding (at least four episodes of bleeding during the previous year) due to SIA were randomly assigned to receive thalidomide at an oral daily dose of 100 mg or 50 mg or placebo for 4 months. Patients were followed for at least 1 year after the end of the 4-month treatment period. The primary end point was effective response, which was defined as a reduction of at least 50% in the number of bleeding episodes that occurred during the year after the end of thalidomide treatment as compared with the number that occurred during the year before treatment. Key secondary end points were cessation of bleeding without rebleeding, blood transfusion, hospitalization because of bleeding, duration of bleeding, and hemoglobin levels.
RESULTS: Overall, 150 patients underwent randomization: 51 to the 100-mg thalidomide group, 49 to the 50-mg thalidomide group, and 50 to the placebo group. The percentages of patients with an effective response in the 100-mg thalidomide group, 50-mg thalidomide group, and placebo group were 68.6%, 51.0%, and 16.0%, respectively (P<0.001 for simultaneous comparison across the three groups). The results of the analyses of the secondary end points supported those of the primary end point. Adverse events were more common in the thalidomide groups than in the placebo group overall; specific events included constipation, somnolence, limb numbness, peripheral edema, dizziness, and elevated liver-enzyme levels.
CONCLUSIONS: In this placebo-controlled trial, treatment with thalidomide resulted in a reduction in bleeding in patients with recurrent bleeding due to SIA. (Funded by the National Natural Science Foundation of China and the Shanghai Municipal Education Commission, Gaofeng Clinical Medicine; ClinicalTrials.gov number, NCT02707484.).
参考来源
- Chen H, Wu S, Tang M, et al. Thalidomide for Recurrent Bleeding Due to Small-Intestinal Angiodysplasia. N Engl J Med. 2023. PMID: 37913505. doi:10.1056/NEJMoa2303706
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。